Philips collaborates with Bard Electrophysiology to advance cardiac arrhythmia treatment

31 January 2009

Royal Philips Electronics (NYSE: PHG, AEX: PHI) has announced an agreement with Bard Electrophysiology, a division of CR Bard, Inc., to co-develop new clinical tools that will be designed to help electrophysiologists meet the need for advanced tool to treat patients suffering from arrhythmias.

Challenging heart rhythm disorders, or arrhythmias, require electrophysiology (EP) technologies to pinpoint and ultimately fix problem areas within the heart’s electrical circuitry during an interventional procedure. As EP procedure volume increases worldwide, clinicians are requesting intuitive, advanced tools to help shorten procedure times and gain detailed visualizations for interventions.

Cardiac arrhythmia can lead to serious health risks, including heart failure or stroke. Atrial fibrillation — a heart rhythm disorder characterized by irregular, rapid beating of the atrial chambers — is found in about 2.2 million Americans and 4.5 million Europeans. With robust EP technologies, clinicians may be better able to evaluate and diagnose abnormalities in the heart’s electrical activity.

The goal of the combination of Bard’s LabSystemPRO EP Recording System and Philips’ EP navigator and the Allura Xper FD series is to provide electrophysiologists a faster and easier way to integrate image guidance with mapping and analysis of complex arrhythmias, while offering insights for more accurate interventional navigation. EP physicians and lab staff may also benefit from improved workflow in the EP lab due to integration and compatibility between Philips and Bard technologies.

"Providing simpler and more intuitive approaches to the management of complex arrhythmias is something that fascinates me. Significant advancement in science and technology is frequently made when two seemingly dissimilar techniques are merged. The collaboration between Bard Electrophysiology and Philips is very promising, and I am looking forward to learning more about the potential for these new technologies in my practice," said Michael V Orlov, MD, PhD, director of Arrhythmia Service at Caritas St Elizabeth's Medical Center of Boston and an associate professor of Medicine at Tufts University School of Medicine.

“Philips is dedicated to simplifying heart rhythm care. The relationship with Bard exemplifies our strategy of collaborating with best-in-class companies to develop solutions that address the needs of the electrophysiologists and their patients,” said Gerard Winkels, vice president and general manager, Electrophysiology, for Philips Healthcare. “The collaboration with Bard Electrophysiology will allow us to bring new clinical tools to market aiming to enable our joint customers to perform EP procedures faster and more simply and allow them to provide enhanced care offerings for their patients.”

Dave Hemink, vice president and general manager, Bard Electrophysiology said, “This alliance will provide us the opportunity to fundamentally impact the way that we analyze and diagnose complex arrhythmias. We recognize that current solutions are complex and time consuming. Together with Philips, we will innovate towards simpler approaches to these clinical challenges, with a focus on helping healthcare providers’ EP labs achieve greater business potential through expanded functionality and improved efficiencies.”

Bookmark this page

To top